Bruker (BRKR) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BRKR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BRKR, but not buy additional shares or sell existing shares.
View BRKR analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1 year price targets for Bruker's shares. Their BRKR share price forecasts range from $70.00 to $98.00. On average, they anticipate the company's share price to reach $84.50 in the next year. This suggests a possible upside of 35.0% from the stock's current price.
View analysts price targets for BRKR or view top-rated stocks among Wall Street analysts.

Bruker's stock was trading at $68.35 at the start of the year. Since then, BRKR stock has decreased by 8.4% and is now trading at $62.60.
View the best growth stocks for 2023 here.

Bruker saw a decline in short interest in September. As of September 15th, there was short interest totaling 3,430,000 shares, a decline of 16.1% from the August 31st total of 4,090,000 shares. Based on an average trading volume of 869,700 shares, the short-interest ratio is currently 3.9 days. Currently, 3.5% of the shares of the stock are short sold.
View Bruker's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our BRKR earnings forecast.

Bruker Co. (NASDAQ:BRKR) posted its earnings results on Thursday, August, 3rd. The medical research company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.02. The medical research company had revenue of $681.90 million for the quarter, compared to the consensus estimate of $647.82 million. Bruker had a trailing twelve-month return on equity of 33.24% and a net margin of 11.76%. Bruker's revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.45 EPS.

Bruker declared a quarterly dividend on Wednesday, August 9th. Shareholders of record on Friday, September 1st will be given a dividend of $0.05 per share on Friday, September 15th. This represents a $0.20 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend is Thursday, August 31st.
Read our dividend analysis for BRKR.

ETFs with the largest weight of Bruker (NASDAQ:BRKR) stock in their portfolio include ProShares Nanotechnology ETF (TINY), Fidelity Disruptive Medicine ETF (FMED), Franklin Genomic Advancements ETF (HELX), SPDR Kensho Future Security ETF (FITE), Mid Cap US Equity Select ETF (RNMC), Invesco NASDAQ Next Gen 100 ETF (QQQJ), SPDR S&P Kensho New Economies Composite ETF (KOMP) and iShares Biotechnology ETF (IBB).

Bruker (NASDAQ:BRKR) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.33%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 9.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BRKR will have a dividend payout ratio of 6.87% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BRKR.

Bruker issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $2.55-$2.60 for the period, compared to the consensus estimate of $2.58. The company issued revenue guidance of $2.85 billion-$2.90 billion, compared to the consensus revenue estimate of $2.86 billion.

126 employees have rated Bruker Chief Executive Officer Frank H. Laukien on Glassdoor.com. Frank H. Laukien has an approval rating of 54% among the company's employees. This puts Frank H. Laukien in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 79.0% of employees surveyed would recommend working at Bruker to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bruker investors own include AbbVie (ABBV), CVS Health (CVS), Micron Technology (MU), Cisco Systems (CSCO), Intel (INTC), Alibaba Group (BABA), Walt Disney (DIS), Applied Materials (AMAT), Bank of America (BAC) and Bristol-Myers Squibb (BMY).

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker's stock is owned by many different institutional and retail investors. Top institutional shareholders include Pallas Capital Advisors LLC (10.78%), BlackRock Inc. (7.36%), State Street Corp (2.10%), Alliancebernstein L.P. (1.68%), Geode Capital Management LLC (1.20%) and Goldman Sachs Group Inc. (1.06%). Insiders that own company stock include Cynthia M Friend, Frank H Laukien, Gerald N Herman, Marc A Kastner, Mark Munch and Richard A Packer.
View institutional ownership trends.

Shares of BRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BRKR stock can currently be purchased for approximately $62.60.

Bruker (NASDAQ:BRKR) has a market capitalization of $9.19 billion and generates $2.53 billion in revenue each year. The medical research company earns $296.60 million in net income (profit) each year or $2.16 on an earnings per share basis.

The company employs 8,525 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The official website for the company is www.bruker.com. The medical research company can be reached via phone at (978) 663-3660, via email at investor.relations@bruker.com, or via fax at 978-663-5585.